Meclizine has antiemetic, anticholinergic and antihistaminic properties. It reduces the sensitivity of the labyrinthine apparatus. The action may be mediated through nerve pathways to the vomiting centre (VC) from the chemoreceptor trigger zone (CTZ), peripheral nerve pathways or other CNS centres. Meclizine has an onset of action of 30 to 60 minutes, depending on dosage; its duration of action is 12 to 24 hours.
Acliz Tablet: Each chewable tablet contains Meclizine HCl USP 50 mg.
Prevention and treatment of nausea, vomiting, motion sickness and vertigo.
Nausea and vomiting: 25-50 mg once daily.
Motion sickness: Take an initial dose of 25 to 50 mg, 1 hour prior to travel. May repeat dose every 24 hours for the duration of the journey.
Vertigo: 25 to 100 mg daily in divided doses.
Labyrinthine and vestibular disturbances: 25 to 100 mg daily in divided doses, depending on the clinical response.
Radiotherapy induced nausea and vomiting: 50 mg two to twelve hours prior to radiotherapy.
Hypersensitivity to meclizine.
Due to its potential anticholinergic action, patients with asthma, bronchitis, emphysema, enlarged prostate, glaucoma or urinary tract blockade should take meclizine HCL (like other antiemetics with cautions)
Drowsiness, Dry mouth, urinary retention on rare occasions, and blurred vision have been reported.
Use in pregnancy: Category B. Large scale human studies have not demonstrated adverse fetal effects. It has been demonstrated that, based on available data, Meclizine presents the lowest risk of teratogenicity and is the drug of first choice in treating nausea and vomiting during pregnancy.
Use in lactation: Meclizine may be excreated into breast milk. However problem in humans have not been documented.
Use in children: Safety and efficacy have not been established below 12 years of children
Acliz Tablet: Each box contains 100 tablets in blister pack.
FR
DE